Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis

Tey, Jeremy; Ho, Francis; Koh, Winston T. H.; Chia, David; Ooi, Kiat Huat; Tuan, Jeffrey Kit Loong; Vellayappan, Balamurugan; Soon, Yu Yang

doi:10.1080/0284186x.2021.1880025

Cited by 11 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine cisplatin/carboplatin are some of the most often used combinations of chemotherapy drugs (GC regimens). Patients who aren't good candidates for cystectomy can improve their chances of local tumor management and live longer with the use of adjuvant and palliative radiotherapy 133–135 . It has been massive improvements in immunotherapy and targeted therapy recently.…”

Section: Bladder Cancer Diagnosismentioning

confidence: 99%

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Sharma,

Malviya

2023

Precision Medical Sciences

View full text Add to dashboard Cite

Bladder cancer (BC) accounts for roughly 3% of all cancer diagnoses in developed countries. The prognosis could be improved significantly if the cancer is detected and classified as either muscle‐invasive bladder cancer (MIBC) or non‐muscle‐invasive bladder cancer (NMIBC) as promptly as possible. A potential ray of hope for the treatment of BC has emerged with the rapid development of nanomedicine and microRNAs (miRNAs), which promise to have fewer adverse effects, more tumor‐inhibitory effects, and decreased drug resistance. The complex interplay between hereditary and environmental variables is the root cause of this malignancy. Gene expression can be regulated by miRNAs, which are small, non‐coding RNAs that can either prevent the translation of protein‐coding genes or cleave RNA transcripts at certain locations. Elevated genomics has enabled a more extensive investigation of miRNAs whose expression is considerably different in BC patients compared to healthy volunteers or between BC tumor tissues and peripheral tissues. miRNAs have recently been discovered to be important regulators of BC cell carcinogenicity. Inaccurate diagnoses and prolonged treatment delays are more likely to occur due to the current diagnostic process such as lack of sensitivity and specificity and poor image quality. Patients now have access to a plethora of treatment options, including but not limited to surgery, chemotherapy, immunotherapy, gene therapy, and other innovative medicines, and in some cases, combination therapies. BC is one of the deadliest and most disabling malignancies affecting the urinary tract. Cancer of the urinary bladder has a terrible propensity for being fatal. BC is an intricate illness whose development can be affected by multiple parameters. Standard treatments for BC increase prognosis and survival, although recurrence is a major concern for patients. miRNAs are naturally occurring, small RNA molecules that have been linked to cancer through their expression being dysregulated. miRNAs modulate many cellular activities including proliferation, migration, differentiation, and apoptosis. MiRNA dysregulation is recognized in BC, and miRNAs are used as diagnostic and prognostic indicators. However, this manuscript discusses the recent progress made in nanomedicine and the function of miRNAs in the pathogenesis and targeted therapy of BC.

show abstract

Section: Bladder Cancer Diagnosismentioning

confidence: 99%

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Sharma,

Malviya

2023

Precision Medical Sciences

View full text Add to dashboard Cite

show abstract

“…Therefore, the major regimens are methotrexate, vinblastine, doxorubicin and cisplatin (MVAC), and gemcitabine cisplatin/carboplatin (GC regimen). In addition, adjuvant and palliative radiotherapy can be used as treatments for patients who are not suitable for cystectomy to increase the local tumor control rate and prolong the overall survival of the patients [ 55 , 56 , 57 ]. Immunotherapy and targeted therapy have developed rapidly in recent years.…”

Section: The Current Therapiesmentioning

confidence: 99%

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer

et al. 2022

View full text Add to dashboard Cite

Bladder cancer is a common malignant tumor of the urinary system. Cystoscopy, urine cytology, and CT are the routine diagnostic methods. However, there are some problems such as low sensitivity and difficulty in staging, which must be urgently supplemented by novel diagnostic methods. Surgery, intravesical instillation, systemic chemotherapy, and radiotherapy are the main clinical treatments for bladder cancer. It is difficult for conventional treatment to deal with tumor recurrence, progression and drug resistance. In addition, the treatment agents usually have the defects of poor specific distribution ability to target tumor tissues and side effects. The rapid development of nanomedicine has brought hope for the treatment of bladder cancer in reducing side effects, enhancing tumor inhibition effects, and anti-drug resistance. Overall, we review the new progression of nano-platforms in the diagnosis and treatment of bladder cancer.

show abstract

“…severe hematuria, dysuria, irritative bladder) which possibly affect their quality of life, and international guidelines 4 recommend best supportive care (BSC) over active treatment in this setting. 19 In the case of MIBC, Stereotactic body radiation therapy (SBRT) is currently rarely used, 20,21 although it represents one of the emerging options in treating both primary tumors and (oligo)metastases with either ablative or palliative intent for patients not eligible for curative treatment. 22,23,24 SBRT targeting macroscopic bladder tumor is distinct from the conventional palliative treatment of the whole bladder in some critical aspects: shortening of the treatment course, partial target volume and the hypofractionation of the dose.…”

Section: Introductionmentioning

confidence: 99%

Muscle-invasive bladder cancer in elderly and frail people: Is hypofractionated radiotherapy a feasible approach when no other local options are available?

Marvaso,

Vitullo,

Corrao

et al. 2024

Tumori

View full text Add to dashboard Cite

Aim: The study aims to report the feasibility and safety of palliative hypofractionated radiotherapy targeting macroscopic bladder tumors in a monocentric cohort of frail and elderly bladder cancer patients not eligible for curative treatments. Methods: Patients who underwent hypofractionated radiotherapy to the gross disease or to the tumor bed after transurethral resection of bladder tumor from 2017 to 2021 at the European Institute of Oncology IRCCS, were retrospectively considered. Schedules of treatment were 30 and 25 Gy in 5 fractions (both every other day, and consecutive days). Treatment response was evaluated with radiological investigation and/or cystoscopy. Toxicity assessment was carried out according to RTOG/EORTC v2.0 criteria. Results: A total of 16 patients were included in the study, of these 11 received hypofractionated radiotherapy on the macroscopic target volume and five on the tumor bed after transurethral resection of bladder tumor. No grade (G) >2 acute toxicities were described after treatment for both groups. Only one patient in the group receiving radiotherapy on the macroscopic disease reported G4 GU late toxicity. Ten patients had available follow-up status (median FU time 18 months), of them six had complete response, one had stable disease, and three had progression of disease. The overall response rate and disease control rate were 60% and 70%, respectively. Conclusion: Our preliminary data demonstrate that palliative hypofractionated radiotherapy for bladder cancer in a frail and elderly population is technically feasible, with an acceptable toxicity profile. These outcomes emphasize the potential of this approach in a non-radical setting and could help to provide more solid indications in this underrepresented setting of patients.

show abstract

Palliative radiotherapy for bladder cancer: a systematic review and meta-analysis

Cited by 11 publications

References 20 publications

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer

Muscle-invasive bladder cancer in elderly and frail people: Is hypofractionated radiotherapy a feasible approach when no other local options are available?

Contact Info

Product

Resources

About